Highest-materiality recent filing
Nasdaq Panel denies Aditxt listing; trading suspended June 25, 2026
Nasdaq Hearings Panel denied Aditxt's request to continue listing; trading suspended at open on June 25, 2026.
Amendment increases aggregate principal of senior secured convertible notes to $6,254,355.17.
Aditxt subsidiary Ignite signs $150M business combination with SPAC Copley Acquisition
Ignite Proteomics to merge with SPAC Copley Acquisition Corp at $150M equity value; Ignite holders get Pubco stock at $10/sh.
Issued senior secured convertible notes with aggregate principal of ~$5.17M, comprising $725K new cash and $4.44M rollover of existing March and April 2026 notes.
Aditxt names Jeffrey M. Busch Interim CEO; Amro Albanna steps down
Amro Albanna resigned as CEO and director effective May 31, 2026; Rowena Albanna resigned as COO effective June 5, 2026.
Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11
Stockholders' equity of $(35.17M) as of March 31, 2026, far below Nasdaq's $2.5M minimum.
Aditxt implements 1-for-27 reverse stock split effective May 18, 2026 for Nasdaq compliance
Reverse split ratio 1-for-27; effective 4:01 p.m. ET May 15; trading on split-adjusted basis from May 18.
Aditxt receives Nasdaq delisting notice for bid price non-compliance; to appeal
Nasdaq Staff Determination on May 6, 2026 for closing bid price below $1 for 30 consecutive business days (March 24–May 5, 2026).
Aditxt shareholders approve reverse stock split authorization up to 1:250
All five director nominees elected; Amro Albanna received 122,066 votes for.
Aditxt acquisition target Ignite shows $5.7M net loss, going concern doubt
Ignite incurred net loss of $5.7M for 2025; revenue was only $43.5K (down from $72K in 2024).
Aditxt regains Nasdaq compliance following equity restoration to $3.95M
Nasdaq notified Aditxt on April 1, 2026, that it now complies with Listing Rule 5550(b)(1).
Aditxt increases ATM equity offering by $36.8M to up to $53.4M
Maximum aggregate offering price increased by $36.8M to $53,398,964 under existing ATM agreement.
Aditxt acquires Ignite Proteomics for $36M in preferred stock; issues $3.2M notes
Acquired 100% of Ignite Proteomics for 36,000 Series A-2 Convertible Preferred Shares (stated value $36M).
Aditxt shareholders approve name change to bitXbio, Inc. and reverse stock split authorization
Shareholders approved name change to bitXbio, Inc. (455,456 for, 40,462 against).
Aditxt adjourns special meeting to Feb 13 for reverse split, name change, equity plan votes
Special meeting adjourned to Feb 13, 2026 at 12 PM ET to allow more stockholder voting time.
Aditxt gets Nasdaq extension to regain compliance with $2.5M equity rule
Extension granted Jan 27, 2026; must complete financing and file compliance report by May 15, 2026.
Aditxt receives Nasdaq delisting notice for insufficient stockholders' equity
Nasdaq notified Aditxt on Dec 1, 2025, that it fails to meet minimum $2.5M stockholders' equity requirement.
Aditxt announces 1-for-113 reverse stock split effective Nov 3, 2025 to regain Nasdaq compliance
Reverse split ratio set at 1-for-113; effective at 4:01 p.m. ET Oct 31, trading begins split-adjusted Nov 3.
Aditxt merger with Evofem terminated after shareholder vote fails, end date passes
Evofem terminated the Merger Agreement effective Oct 20, 2025, citing Section 8.1(b)(ii) (end date passed) and 8.1(b)(iv) (failure to obtain shareholder approval at the special meeting).
Aditxt shareholders approve reverse stock split authorization up to 1:250
Reverse split authorization passed: 1,178,583 For, 473,001 Against, 13,596 Abstain.
Aditxt issues $212.5K senior notes at 10% OID, adjourns annual meeting for reverse split vote
Issued senior unsecured notes: $212,500 principal for $170,000 (20% OID), 10% interest, matures Sept 30, 2025.
Aditxt, Evofem amend merger agreement; adds Series G-1 preferred, new closing conditions
Amendment No. 6 adds Evofem Series G-1 Preferred Stock to the definition of Unconverted Company Preferred Stock.
CEO presents Pearsanta IPO plans; commercialization target Q1 2026
CEO Amro Albanna presented at Wall Street Reporter livestream; discussed Pearsanta IPO plans.
Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned
Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.
Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025
Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).
Aditxt receives $190K insider loans from CEO and CInO; issues 600K-share warrant to consultant
CEO Amro Albanna loaned $90,000 and CInO Shahrokh Shabahang loaned $100,000 at 7.5% interest, due July 20, 2025.
Aditxt appoints Evofem CEO Saundra Pelletier to board; officer loans $70K
Board appoints Saundra Pelletier (CEO of Evofem) as director, effective June 5, 2025.
Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.
Aditxt files amendment with Evofem Q1 results; merger deadline extended to Sep 30, 2025
Evofem Q1 2025 product sales net $845K, down 77% YoY from $3.6M; net income of $956K vs net loss $4.8M.
Aditxt terminates Appili acquisition; eliminates ~$16M closing obligations
Termination of Arrangement Agreement with Appili effective May 31, 2025.
Aditxt Q3 plan: simplify cap table, cut debt, advance Adimune and Pearsanta
CEO states goal is transition from speculative to growth stage by end of Q3 2025.
Issued $3,114,285.71 principal note for $2M purchase price (30% OID); 10% interest, 20% on default.
Completed toxicology, bio-distribution, persistence, and antibody formation studies for ADI-100 with no safety flags.
Pearsanta received IRB approval to start clinical studies for a blood-based diagnostic test for endometriosis using mitochondrial DNA analysis.
Aditxt secures call option to purchase $25M Evofem convertible notes for $13M
Aditxt granted call option to acquire Evofem convertible notes (aggregate $25M principal) and purchase rights from Adjuvant funds for $13M.
Aditxt regains Nasdaq minimum bid price compliance, removes panel monitoring
Regained full compliance with Nasdaq listing requirements; no longer under panel monitoring.
Aditxt regains Nasdaq minimum bid price compliance; hearing cancelled
Received Nasdaq letter on April 8, 2025 confirming compliance with Listing Rule 5550(a)(2).
Aditxt invests $1.5M in Evofem via convertible note and warrant as part of merger extension
Aditxt purchased a $2,307,692 senior subordinated convertible note of Evofem and a warrant for 149,850,150 shares of Evofem common stock for $1,500,000.
On June 2, 2026, Brian Brady resigned as non-executive Chairman of the Board as well as a member of the Board, effective immediately.
On June 2, 2026, Christopher J. Porcelli notified the Company of his decision to resign as General Counsel, Chief People Officer and Corporate Secretary of Aditxt, Inc. (the “Company”) effective immediately.
On May 29, 2026, Amro Albanna notified the Company of his decision to resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
On May 31, 2026, Rowena Albanna notified the Company of her decision to resign as Chief Operating Officer of the Company, effective June 5, 2026.
On May 29, 2026, Amro Albanna notified the Company of his decision to resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
On May 31, 2026, the Board appointed Brian Brady, an independent director of the Company, to serve as non-executive Chairman of the Board, effective as of such date.
On May 31, 2026, Shahrokh Shabahang resigned as a member of the Board, effective immediately.
On May 31, 2026, the Board appointed Jeffrey M. Busch, age 68, to serve as Interim Chief Executive Officer of the Company, effective as of such date.
On June 5, 2025, the Board of Directors (the “ Board ”) of the Company, with the recommendation of the Nominating and Corporate Governance Committee, appointed Ms. Saundra Pelletier as a member of the Board.
On November 3, 2023, Namvar Kiaie notified the board of directors (the “Board”) of the Company that he intends to resign as a member of the Board and as a member of the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee effective November 3, 2023.
On November 3, 2023, the Board, with the recommendation of the Nominating and Corporate Governance Committee, appointed Mr. Charles Athle Nelson as a member of the Board and as a member of the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, to become effective on November 3, 2023 following the resignation of Mr. Kiaie.
As previously reported, on July 21, 2023, Matthew Shatzkes tendered his resignation as Chief Legal Officer, General Counsel and Corporate Secretary of Aditxt, Inc. (the “Company”).
Max materiality 0.95 · Median 0.65 · Most common event other_material